MA51870A - Procédé pour la préparation de composés coupleurs de médicaments - Google Patents

Procédé pour la préparation de composés coupleurs de médicaments

Info

Publication number
MA51870A
MA51870A MA051870A MA51870A MA51870A MA 51870 A MA51870 A MA 51870A MA 051870 A MA051870 A MA 051870A MA 51870 A MA51870 A MA 51870A MA 51870 A MA51870 A MA 51870A
Authority
MA
Morocco
Prior art keywords
preparation
coupling compounds
drug coupling
drug
compounds
Prior art date
Application number
MA051870A
Other languages
English (en)
Inventor
Sophie Blanchard
James Coats
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MA51870A publication Critical patent/MA51870A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
MA051870A 2017-11-30 2018-11-29 Procédé pour la préparation de composés coupleurs de médicaments MA51870A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762593104P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
MA51870A true MA51870A (fr) 2020-10-07

Family

ID=66665808

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051870A MA51870A (fr) 2017-11-30 2018-11-29 Procédé pour la préparation de composés coupleurs de médicaments

Country Status (15)

Country Link
US (2) US11612666B2 (fr)
EP (1) EP3717016A4 (fr)
JP (2) JP7402159B2 (fr)
KR (1) KR20200094185A (fr)
CN (1) CN111417408B (fr)
AU (1) AU2018375412A1 (fr)
BR (1) BR112020010503A2 (fr)
CA (1) CA3082165A1 (fr)
EA (1) EA202091340A1 (fr)
IL (1) IL274757A (fr)
MA (1) MA51870A (fr)
MX (1) MX2020005565A (fr)
SG (1) SG11202004698RA (fr)
WO (1) WO2019108797A1 (fr)
ZA (1) ZA202003037B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745738C1 (ru) * 2019-05-20 2021-03-31 МэбПлекс Интернэшнл Ко., Лтд. Однореакторный способ получения промежуточного продукта конъюгата антитело-лекарственное средство
JP7289799B2 (ja) * 2019-10-23 2023-06-12 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 オリゴペプチドリンカー中間体及びその製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
RU2009114154A (ru) 2006-09-15 2010-10-20 Энзон Фармасьютикалз, Инк. (Us) Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры
JP5358566B2 (ja) 2007-06-21 2013-12-04 アムジエン・インコーポレーテツド シナカルセトおよびその塩を合成する方法
JP6581774B2 (ja) * 2011-05-27 2019-09-25 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
EP3925627A1 (fr) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Conjugués de médicaments et leurs utilisations
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
US9533483B2 (en) 2014-09-26 2017-01-03 Kimberly-Clark Worldwide, Inc. Apparatus for and method of shaping and applying a segment to a moving web

Also Published As

Publication number Publication date
US20240042052A1 (en) 2024-02-08
JP7402159B2 (ja) 2023-12-20
KR20200094185A (ko) 2020-08-06
ZA202003037B (en) 2023-12-20
AU2018375412A1 (en) 2020-05-28
BR112020010503A2 (pt) 2020-10-20
SG11202004698RA (en) 2020-06-29
CN111417408A (zh) 2020-07-14
US11612666B2 (en) 2023-03-28
MX2020005565A (es) 2020-08-20
US20200360532A1 (en) 2020-11-19
JP2021505542A (ja) 2021-02-18
CA3082165A1 (fr) 2019-06-06
CN111417408B (zh) 2024-04-23
IL274757A (en) 2020-07-30
EP3717016A4 (fr) 2021-09-01
JP2023164652A (ja) 2023-11-10
WO2019108797A1 (fr) 2019-06-06
EP3717016A1 (fr) 2020-10-07
EA202091340A1 (ru) 2020-10-16

Similar Documents

Publication Publication Date Title
MA51988A (fr) Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
MA41200B1 (fr) Procédé pour la préparation d'un composé diarylthiohydantoïne
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA52906A (fr) Procédé de préparation d'amg 416
MA43099A (fr) Procédé pour la préparation de chlorure de vinyle
MA41203A (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
GB202106894D0 (en) Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone)
MA50169A (fr) Procédé de production d'un électrocatalyseur
MA49700A (fr) Procédé amélioré pour la préparation de dérivés d'aminopyrimidine
MA42423A (fr) Procédé de préparation d'un revêtement
MA39480A (fr) Nouveau procédé pour la préparation de prostaglandines de haute pureté
MA45768A (fr) Procédé pour la préparation de compositions d'immunoglobulines
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
PL3737678T3 (pl) Sposób wytwarzania dipodstawionych związków diaryloksybenzoheterodiazolowych
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
MA44680A (fr) Compositions et procédés pour la production de composés
IL276483B1 (en) A continuous process for the preparation of trazodone
MA42264A (fr) Procédé de préparation d'oltipraz
IL268835B (en) A process for the preparation of 2-cyanoimidazole compounds
MA51510A (fr) Procédés de préparation de dérivés d'indolinobenzodiazépine
MA49555A (fr) Procédé amélioré de préparation d'imetelstat